NCT02217488View on ClinicalTrials.gov

Single Ascending Dose Tolerability Study of DG3173

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

September 30, 2008

Conditions
Healthy
Interventions
DRUG

DG3173

DRUG

Placebo

Sponsors
All Listed Sponsors
collaborator

DeveloGen AG, Germany

UNKNOWN

lead

Aspireo Pharmaceuticals Limited

INDUSTRY